Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vascular protection with cilazapril.

J P Clozel1, J S Powell, H Kuhn

  • 1Department of Pharmaceutical Research, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Drugs
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

We thrive not when we've done it all, but when we still have more to do (S. Lewis).

Journal of children's orthopaedics·2022
Same author

Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2019
Same author

<i>LABOR OMNIA VINCIT IMPROBUS</i> - Labour conquers all things: An Impact Factor for JCO!

Journal of children's orthopaedics·2018
Same author

Impact of Single Center Treatment on Ewing Sarcoma 10-Year Long Term Survival Rates.

Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca·2018
Same author

Treatment of shepherd's crook deformity in patients with polyostotic fibrous dysplasia using a new type of custom made retrograde intramedullary nail: a technical note.

Journal of children's orthopaedics·2017
Same author

<i>PER ASPERA AD ASTRA</i>: through hardships to the stars.

Journal of children's orthopaedics·2017

Cilazapril effectively reduced cardiac hypertrophy and improved blood flow in hypertensive rats. This hypertension drug also prevented blood vessel narrowing after injury, suggesting potential for preventing restenosis after angioplasty.

Area of Science:

  • Cardiovascular Pharmacology
  • Hypertension Research
  • Vascular Biology

Background:

  • Hypertension-induced medial hypertrophy of coronary arteries reduces vascular reserve.
  • Vascular injury, such as from angioplasty, can lead to restenosis due to myointimal proliferation.

Purpose of the Study:

  • To investigate the effects of cilazapril on cardiac hypertrophy and coronary vascular resistance in spontaneously hypertensive rats (SHR).
  • To evaluate cilazapril's impact on vascular reserve in cerebral, mesenteric, and renal arteries of SHR.
  • To assess cilazapril's preventive effect on myointimal proliferation in a rat model of vascular injury.

Main Methods:

  • Administration of cilazapril (10 mg/kg daily) to SHR at the onset and after the development of hypertension.
  • Measurement of cardiac hypertrophy, coronary vascular resistance, and maximal coronary blood flow in isolated perfused hearts.

Related Experiment Videos

  • Assessment of cerebral, mesenteric, and renal vascular reserve in SHR.
  • Induction of vascular injury using ballooning in rats and evaluation of myointimal proliferation with and without cilazapril treatment.

    • Main Results:

    • Cilazapril decreased cardiac hypertrophy and minimal coronary vascular resistance by 40% in SHR.
    • In established hypertension, cilazapril normalized arterial pressure, increased maximal coronary blood flow by 96%, and reduced medial hypertrophy.
    • Cilazapril improved cerebral vascular reserve and significantly prevented myointimal proliferation post-vascular injury, an effect independent of blood pressure reduction.

    Conclusions:

    • Cilazapril effectively mitigates cardiac hypertrophy and improves coronary and cerebral vascular function in hypertensive rats.
    • The drug demonstrates a significant preventive effect against neointima formation, suggesting a potential role in preventing restenosis after angioplasty.
    • Ongoing clinical trials are evaluating cilazapril's efficacy in preventing restenosis post-coronary angioplasty.